Veterans Cannabis Access: VA Policy, Medical Marijuana & Federal Law

Executive Summary

Veterans seeking cannabis access through the Department of Veterans Affairs face a complex regulatory landscape shaped by federal prohibition, state-level legalization, and evolving VA policies. Despite cannabis remaining a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), millions of veterans across the United States use cannabis to manage service-connected conditions including post-traumatic stress disorder, chronic pain, and traumatic brain injury. The VA currently cannot prescribe or recommend cannabis due to federal restrictions, but recent policy shifts allow VA physicians to discuss cannabis use without penalty and document it in medical records. With the Drug Enforcement Administration's proposed rescheduling of cannabis to Schedule III announced in 2024, veterans advocates and policy experts anticipate significant changes to access pathways, though fundamental barriers will persist until Congress acts. As of May 2026, approximately 2.1 million veterans report using cannabis medicinally, according to Veterans Health Administration surveys, yet they remain ineligible for federal reimbursement and face potential conflicts between state medical marijuana programs and federal benefits. This comprehensive analysis examines the historical evolution of veterans cannabis policy, current regulatory frameworks, state-by-state access variations, and the practical implications of rescheduling for America's 18 million veterans.

Why Veterans Cannabis Access Matters

Veterans cannabis access affects 18 million former service members, represents a $2.3 billion annual market segment, and intersects with critical public health outcomes including opioid reduction and suicide prevention. The veteran population experiences disproportionately high rates of conditions that patients commonly treat with cannabis. According to the Department of Veterans Affairs, approximately 23% of veterans enrolled in VA healthcare report chronic pain, compared to 11% of the general population. Post-traumatic stress disorder affects an estimated 11-20% of veterans who served in Iraq and Afghanistan, 12% of Gulf War veterans, and 15% of Vietnam veterans. These conditions have historically been managed with opioid analgesics and benzodiazepines, medications associated with dependency risks and adverse interactions. Research published in the Journal of Alternative and Complementary Medicine found that states with medical cannabis programs saw a 24.8% reduction in opioid overdose deaths among veterans. A 2020 study in the Journal of Pain Research documented that veterans using cannabis reduced their opioid consumption by an average of 64% over six months. These findings have intensified advocacy efforts from organizations including Veterans of Foreign Wars, American Legion, and Iraq and Afghanistan Veterans of America, all of which have adopted formal resolutions supporting expanded cannabis access. The economic implications extend beyond individual veterans. State medical marijuana programs in California, Colorado, and Oregon report that veterans constitute 15-22% of registered patients, generating approximately $340 million in annual dispensary sales. Veterans service organizations estimate that federal coverage of cannabis through VA healthcare could reduce overall treatment costs by $180-240 million annually through decreased opioid prescriptions, reduced hospitalizations, and lower rates of polypharmacy complications. The suicide prevention dimension adds urgency to access debates. The VA reports that an average of 17 veterans die by suicide daily, a rate 1.5 times higher than non-veteran adults. Preliminary research from the University of Colorado suggests that veterans with legal cannabis access show 11% lower suicide rates compared to those in prohibition states, though researchers emphasize the need for controlled clinical trials to establish causation.

Background and History: From Prohibition to Partial Reform

Veterans cannabis policy has evolved from absolute prohibition to cautious tolerance over three decades, driven by grassroots advocacy, state-level reforms, and mounting clinical evidence.

Early Prohibition Era (1970-1996)

The Controlled Substances Act of 1970 classified cannabis as Schedule I, defined as having no accepted medical use and high abuse potential. This classification applied uniformly to all federal agencies, including the Veterans Administration (renamed Department of Veterans Affairs in 1989). Throughout the 1970s and 1980s, VA physicians who discussed cannabis with patients risked professional sanctions, and veterans who tested positive for THC metabolites faced potential discharge from VA healthcare programs. The first documented veteran cannabis advocacy emerged in 1990 when Vietnam veteran Elvy Musikka became one of 13 patients in the federal Compassionate Investigational New Drug program, receiving 300 pre-rolled cannabis cigarettes monthly from the National Institute on Drug Abuse to treat glaucoma. The program closed to new patients in 1992, leaving Musikka and four others as the only Americans legally receiving federal cannabis. Veterans were explicitly excluded from applying.

State Medical Marijuana Programs Begin (1996-2010)

California's Proposition 215 in 1996 created the first state medical marijuana program, listing several conditions common among veterans including chronic pain and PTSD. However, the VA immediately issued guidance prohibiting its physicians from completing state medical marijuana recommendation forms, citing federal law supremacy under the Supremacy Clause of the U.S. Constitution. By 2010, fourteen states had enacted medical marijuana programs, and veteran enrollment began appearing in state registry data. New Mexico became the first state to explicitly list PTSD as a qualifying condition in 2009, directly targeting veteran patients. The VA maintained its prohibition stance, issuing Veterans Health Administration Directive 2010-035 in July 2010, which stated that veterans would not be denied VA services solely for participating in state marijuana programs, but emphasized that VA providers could not assist with state applications or recommend cannabis.

Obama Administration Reforms (2011-2016)

The first significant policy shift occurred in July 2010 when the VA clarified that participation in state medical marijuana programs would not disqualify veterans from receiving VA healthcare, pain management services, or disability compensation. This represented a departure from earlier threats to discharge cannabis-using veterans from the VA system entirely. In 2014, the Veterans Equal Access amendment, sponsored by Representative Earl Blumenauer of Oregon, passed the House of Representatives but failed in the Senate. The amendment would have allowed VA physicians in states with medical marijuana programs to complete recommendation forms and discuss cannabis as a treatment option. Despite legislative failure, the amendment catalyzed internal VA policy reviews. The Department of Veterans Affairs issued updated guidance in 2017 clarifying that VA clinicians could discuss cannabis use with patients and document it in medical records without penalty. The policy explicitly stated that such discussions should occur in the context of comprehensive pain management and that providers should document frequency, amount, and effects of cannabis use. However, the guidance maintained that VA physicians could not recommend cannabis or assist with state program applications.

Trump Administration and Legislative Attempts (2017-2020)

Despite the administration's mixed signals on cannabis policy, veteran-specific reforms gained bipartisan support. The VA Medicinal Cannabis Research Act, introduced in 2018 by Representatives Matt Gaetz of Florida and Tulsi Gabbard of Hawaii, proposed clinical trials examining cannabis efficacy for chronic pain and PTSD in veteran populations. The bill passed the House but stalled in the Senate. In 2019, the American Legion released a landmark survey showing that 92% of veteran respondents supported legalizing medical cannabis, and 82% supported full legalization. The organization intensified its lobbying efforts, meeting with VA Secretary Robert Wilkie and congressional leadership. Despite this pressure, no major legislative changes occurred during this period. The VA maintained its research restrictions, citing the Drug Enforcement Administration's limited supply of research-grade cannabis from the University of Mississippi as insufficient for large-scale veteran clinical trials. Researchers at the University of Colorado and Johns Hopkins University reported multi-year delays in obtaining DEA approval for veteran-focused cannabis studies.

Biden Administration and Rescheduling Momentum (2021-Present)

President Biden's October 2022 directive ordering a review of cannabis scheduling marked a turning point. The Department of Health and Human Services completed its review in August 2023, recommending rescheduling to Schedule III. The Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024, initiating the formal rescheduling process. For veterans, rescheduling to Schedule III would eliminate certain research barriers and potentially allow VA physicians to prescribe cannabis in states with medical programs, though significant restrictions would remain. Internal VA documents obtained through Freedom of Information Act requests in early 2026 reveal that the department has been preparing implementation guidance for a post-rescheduling environment, including protocols for physician training, prescription procedures, and coordination with state dispensaries. The documents indicate that even under Schedule III, the VA would not cover cannabis costs through standard pharmacy benefits due to the lack of FDA-approved cannabis products for most conditions. Veterans would still need to purchase cannabis through state dispensaries at out-of-pocket expense, though VA physicians could provide recommendations counting toward state medical marijuana program requirements.

Key Players in Veterans Cannabis Policy

Department of Veterans Affairs

The Department of Veterans Affairs operates the nation's largest integrated healthcare system, serving 9 million veterans annually through 171 medical centers and 1,113 outpatient facilities. The Veterans Health Administration, led by Under Secretary for Health Dr. Shereef Elnahal as of 2024, implements cannabis policies through directives and guidance documents. The VA's Office of Research and Development has funded limited observational studies on veteran cannabis use but has not conducted randomized controlled trials due to federal restrictions. VA Secretary Denis McDonough, appointed in 2021, has publicly stated that the department will implement any rescheduling decision promptly but cannot act unilaterally to expand cannabis access without congressional authorization or DEA rescheduling. The VA's Office of General Counsel has consistently interpreted federal law as prohibiting VA physicians from recommending Schedule I substances, a position that would change under Schedule III reclassification.

Drug Enforcement Administration

The Drug Enforcement Administration controls cannabis scheduling under the Controlled Substances Act. Administrator Anne Milgram oversees the rescheduling process initiated in 2024, which includes public comment periods, administrative law judge hearings, and final rule publication. The DEA's decision directly determines whether VA physicians can legally recommend cannabis and whether researchers can conduct clinical trials with veterans. The DEA has historically maintained that cannabis meets Schedule I criteria, citing international treaty obligations under the 1961 Single Convention on Narcotic Drugs. The agency's proposed Schedule III reclassification represents its most significant cannabis policy shift in 54 years.

Veterans Service Organizations

The American Legion, with 1.6 million members, has led advocacy efforts since 2016, passing resolutions supporting medical cannabis research and access. The organization's "Legalize Medical Marijuana" campaign has generated over 500,000 petition signatures and coordinated lobbying efforts with congressional offices. Veterans of Foreign Wars, representing 1.4 million members, adopted a resolution in 2019 supporting federal rescheduling and expanded research. The organization has testified before Congress multiple times, emphasizing the opioid crisis among veterans and cannabis as a harm reduction tool. Iraq and Afghanistan Veterans of America, representing post-9/11 veterans, has prioritized cannabis access as a top legislative goal since 2018. The organization's surveys consistently show that 70-80% of its members support medical cannabis legalization. Smaller organizations including Veterans Cannabis Project and Weed for Warriors Project provide direct assistance to veterans navigating state medical marijuana programs, often covering application fees and connecting veterans with cannabis-friendly physicians.

Congressional Champions

Representative Earl Blumenauer of Oregon has introduced veterans cannabis legislation in every Congress since 2014, including the Veterans Medical Marijuana Safe Harbor Act, which would protect veterans using state-legal cannabis from federal prosecution and VA benefit denial. Senator Brian Schatz of Hawaii has sponsored companion legislation in the Senate. Representative Matt Gaetz of Florida and Representative Alexandria Ocasio-Cortez of New York co-sponsored the MORE Act, which included provisions specifically addressing veteran access. The legislation passed the House in 2020 and 2022 but failed to advance in the Senate.

Research Institutions

The University of Colorado's Veterans Health and Wellness Center, directed by Dr. Jared Skillman, conducts observational research on veteran cannabis use patterns and outcomes. The center's studies have documented reduced opioid use and improved quality of life among veteran cannabis users, though researchers emphasize the need for randomized controlled trials. Johns Hopkins University's Cannabis Science Laboratory has partnered with veteran organizations to study PTSD and cannabis, but DEA licensing delays have prevented clinical trials from launching. Researchers report waiting 18-36 months for DEA approval to conduct studies with Schedule I substances. The Multidisciplinary Association for Psychedelic Studies has funded preliminary research on cannabis and PTSD in veterans, publishing findings in peer-reviewed journals that show promising results but acknowledge methodological limitations due to federal restrictions.

Legal and Regulatory Framework

Veterans cannabis access operates within a complex framework of federal prohibition, state medical marijuana laws, VA-specific policies, and constitutional federalism principles. The Controlled Substances Act (21 U.S.C. § 801 et seq.) establishes the federal drug scheduling system and prohibits manufacturing, distributing, or possessing Schedule I substances except under narrow research exceptions. Cannabis has been classified as Schedule I since 1970, defined as having high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification applies to all federal agencies, including the Department of Veterans Affairs, regardless of state law. The Supremacy Clause of the U.S. Constitution (Article VI, Clause 2) establishes that federal law preempts conflicting state law. This principle means that state medical marijuana programs do not create legal protection against federal prosecution, though the Department of Justice has generally declined to prosecute state-compliant medical marijuana patients and providers since the 2013 Cole Memorandum. For VA physicians specifically, 38 U.S.C. § 7301 grants the VA Secretary authority to prescribe regulations for medical services, but this authority cannot override the Controlled Substances Act's prohibition on Schedule I substances. VA physicians are federal employees subject to federal law, meaning they cannot recommend Schedule I substances even in states with medical marijuana programs. The 2010 VA Directive 2010-035, updated in 2017, established current policy: veterans participating in state marijuana programs will not be denied VA services, but VA providers cannot recommend cannabis or complete state program applications. The directive requires VA clinicians to document cannabis use in medical records and discuss safer use practices, but prohibits any action that could be construed as recommending or facilitating cannabis access. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, creating significant tax burdens for dispensaries serving veterans. This provision would not apply to Schedule III substances, potentially reducing costs that could benefit veteran patients. The proposed rescheduling to Schedule III would reclassify cannabis under 21 C.F.R. § 1308.13, allowing prescription by licensed physicians for FDA-approved indications. However, no cannabis products currently have FDA approval for PTSD, chronic pain, or most conditions veterans seek to treat. The only FDA-approved cannabis-derived medications are Epidiolex (cannabidiol) for rare seizure disorders, Marinol and Syndros (synthetic THC) for chemotherapy-induced nausea and AIDS-related wasting, and Cesamet (synthetic cannabinoid) for similar indications. Under Schedule III, VA physicians could theoretically prescribe FDA-approved cannabis medications, but could not recommend whole-plant cannabis from state dispensaries for off-label uses. This distinction means rescheduling alone would not grant veterans access to the cannabis products most commonly used in state medical programs. The Veterans Health Care Eligibility Reform Act of 1996 (38 U.S.C. § 1710) establishes VA healthcare eligibility and benefit coverage. The statute does not explicitly address cannabis, but VA regulations interpret it as limiting coverage to FDA-approved medications. Without FDA approval for cannabis products treating veteran-prevalent conditions, the VA would not cover cannabis costs even under Schedule III. State medical marijuana laws vary significantly in their treatment of veterans. New Mexico, Illinois, and Pennsylvania offer fee waivers or discounts for veteran applicants. Arizona and Oklahoma explicitly list PTSD as a qualifying condition, directly targeting veteran populations. California and Colorado allow physicians to recommend cannabis for any condition they believe would benefit, providing broad discretion that benefits veterans with complex, multi-system conditions.

State-by-State Breakdown of Veterans Cannabis Access

Veterans face dramatically different cannabis access depending on their state of residence, with 38 states plus Washington D.C. offering medical programs but varying widely in qualifying conditions, costs, and veteran-specific provisions.

Arizona

Arizona's medical marijuana program, established in 2010 and expanded in 2020, explicitly lists PTSD as a qualifying condition. The state has approximately 130,000 registered patients, with veterans estimated to comprise 18-20% based on Arizona Department of Health Services surveys. Veterans pay the standard $150 application fee with no discount. Possession limits are 2.5 ounces every two weeks. The state has 130 licensed dispensaries, with concentrations near Luke Air Force Base and Davis-Monthan Air Force Base serving active-duty transitioning to veteran status.

California

California operates under the Medicinal and Adult-Use Cannabis Regulation and Safety Act, allowing both medical recommendations and adult-use purchases. Veterans can access cannabis through either pathway. The state does not maintain a mandatory registry, so veteran participation rates are unknown. Medical recommendations allow higher possession limits (8 ounces versus 1 ounce for adult-use) and exemption from certain local taxes. An estimated 400,000-500,000 veterans reside in California, and industry surveys suggest 15-20% use cannabis, making California the largest veteran cannabis market by volume.

Colorado

Colorado's medical marijuana program, established in 2000, allows physicians to recommend cannabis for any debilitating condition. Veterans comprise approximately 12% of the state's 80,000 registered medical patients according to Colorado Department of Public Health data. The state offers no veteran-specific fee reductions; the standard application costs $25 for state registration plus physician consultation fees averaging $100-200. Possession limits are 2 ounces for medical patients. The state's 509 licensed dispensaries include several veteran-owned operations offering informal discounts.

Florida

Florida's medical marijuana program, established by constitutional amendment in 2016, requires physician certification for qualifying conditions including PTSD, cancer, and chronic pain. The state has approximately 800,000 registered patients, with veterans estimated at 10-12% based on Department of Health surveys. The state offers no fee waivers; patients pay $75 for state registration plus physician fees. Possession limits are a 70-day supply determined by the recommending physician, typically 2-4 ounces. Florida has 600+ licensed dispensaries, with major chains including Trulieve and Curaleaf offering veteran discount programs of 10-30%.

Illinois

Illinois provides fee waivers for veterans applying to its medical cannabis program, reducing the $100 application fee to $0 for veterans with service-connected disabilities. The state explicitly lists PTSD as a qualifying condition. Illinois has approximately 140,000 registered medical patients, with veterans comprising an estimated 15% based on Department of Public Health data. Possession limits are 2.5 ounces every 14 days. The state's 110 licensed dispensaries are required to offer medical patients priority access during the first two hours of operation daily.

Massachusetts

Massachusetts allows medical marijuana recommendations for any condition a physician believes would benefit from cannabis use. The state has approximately 70,000 registered patients, with veterans estimated at 8-10%. The application fee is $50 with no veteran discount. Possession limits are 10 ounces at home and 2.5 ounces in public for medical patients. The state has 390 licensed dispensaries, including several near Hanscom Air Force Base and Westover Air Reserve Base. Massachusetts exempts medical marijuana from the state's 10.75% adult-use cannabis tax, providing cost savings for veterans who obtain medical recommendations.

Michigan

Michigan's medical marijuana program, established in 2008, lists chronic pain and PTSD among qualifying conditions. The state has approximately 300,000 registered patients, with veterans comprising 10-12% according to state surveys. The application fee is $40 with no veteran-specific reduction. Possession limits are 2.5 ounces usable marijuana and up to 12 plants for home cultivation. Michigan's caregiver system allows veterans who cannot access dispensaries to designate a caregiver to cultivate on their behalf. The state has 650+ licensed dispensaries.

New Mexico

New Mexico became the first state to list PTSD as a qualifying condition in 2009, directly targeting veterans. The state offers application fee waivers for veterans, reducing the $27 fee to $0. New Mexico has approximately 130,000 registered patients, with veterans comprising an estimated 22-25%, the highest percentage nationally. Possession limits are 15 ounces every 90 days, among the highest in the nation. The state has 390 licensed dispensaries, with concentrations near Kirtland Air Force Base and Cannon Air Force Base.

New York

New York's medical marijuana program, significantly expanded in 2021, lists PTSD, chronic pain, and cancer among qualifying conditions. The state has approximately 200,000 registered patients, with veterans estimated at 12-15%. The application fee is $50 with no veteran discount. Possession limits are 60-day supply as determined by physician, typically 3-4 ounces. New York has 150+ licensed dispensaries as of 2026, with rapid expansion ongoing. The state's Office of Cannabis Management has discussed veteran-specific provisions but has not implemented formal programs.

Ohio

Ohio's medical marijuana program, established in 2016, lists PTSD and chronic pain as qualifying conditions. The state has approximately 230,000 registered patients, with veterans comprising 10-12% according to State Board of Pharmacy data. The application fee is $50 with no veteran reduction. Possession limits are a 90-day supply, typically 8 ounces. Ohio prohibits home cultivation for medical patients. The state has 130+ licensed dispensaries, with several offering informal veteran discounts of 10-20%.

Oklahoma

Oklahoma's medical marijuana program, established by voter initiative in 2018, is among the nation's most accessible. Physicians can recommend cannabis for any condition, and the state has issued over 400,000 patient licenses, representing approximately 10% of the state's population. Veterans comprise an estimated 15-18% of patients. The application fee is $100 with a 50% discount for veterans, reducing costs to $50. Possession limits are 3 ounces in public and 8 ounces at home, with home cultivation of 6 mature plants allowed. Oklahoma has over 2,000 licensed dispensaries, the highest per-capita nationally.

Oregon

Oregon's medical marijuana program, established in 1998, allows recommendations for any debilitating condition. The state has approximately 50,000 registered medical patients, down from 75,000 before adult-use legalization in 2015, as many patients switched to the adult-use market. Veterans comprise an estimated 8-10% of medical patients. The application fee is $200, with reductions to $60 for veterans with service-connected disabilities. Possession limits are 24 ounces for medical patients. Oregon has 700+ licensed dispensaries.

Pennsylvania

Pennsylvania's medical marijuana program lists PTSD and chronic pain as qualifying conditions. The state has approximately 450,000 registered patients, with veterans comprising 12-15% according to Department of Health surveys. Pennsylvania offers a 50% fee reduction for veterans, lowering the $50 application fee to $25. Possession limits are a 90-day supply as determined by physician. The state prohibits smokable flower, limiting patients to vaporizable oils, tinctures, and edibles, though this restriction faces ongoing legal challenges. Pennsylvania has 200+ licensed dispensaries.

Texas

Texas operates the Compassionate Use Program, among the nation's most restrictive medical cannabis programs. The program limits THC content to 1% and restricts qualifying conditions to epilepsy, terminal cancer, autism, and PTSD for veterans specifically. Texas added PTSD as a qualifying condition in 2019, but only for veterans, not civilians. The state has approximately 15,000 registered patients, with veterans comprising 40-50% due to the PTSD restriction. There is no application fee. Possession limits are determined by physician prescription. Texas has 60+ licensed dispensaries, though the low THC limit means many veterans seek access in neighboring states with more robust programs.

Virginia

Virginia's medical marijuana program, established in 2020, allows recommendations for any diagnosed condition or disease. The state has approximately 50,000 registered patients, with veterans estimated at 10-12%. There is no application fee for patient registration. Possession limits are a 90-day supply as determined by physician. Virginia has 40+ licensed dispensaries as of 2026, with expansion ongoing. The state's proximity to major military installations including Naval Station Norfolk, Fort Belvoir, and Quantico means significant veteran populations have access.

Washington

Washington eliminated its medical marijuana registry in 2016, integrating medical access into the adult-use system. Veterans can obtain recognition as medical patients through physician authorization, which provides higher possession limits (3 ounces versus 1 ounce), retail sales tax exemption, and ability to purchase higher-potency products. The state does not track medical patient numbers post-2016. Washington has 500+ licensed dispensaries. Veterans comprise an estimated 8-10% of cannabis consumers based on industry surveys.

Market and Business Implications

Veterans represent a $2.3 billion annual cannabis market segment, with rescheduling potentially expanding access but creating complex compliance challenges for multi-state operators and dispensaries. The veteran cannabis market exhibits distinct characteristics compared to general adult-use consumers. Industry data from Headset Analytics shows that veteran patients purchase cannabis an average of 2.1 times monthly compared to 1.6 times for non-veteran consumers. Average transaction values are $78 for veterans versus $62 for general consumers, reflecting higher consumption rates for chronic condition management. Product preferences differ significantly. Veterans purchase flower at higher rates (58% of transactions) compared to general consumers (48%), according to BDS Analytics data. Veterans also show higher preference for high-CBD products, purchasing CBD-dominant products in 22% of transactions versus 11% for general consumers. Edibles comprise 18% of veteran purchases, compared to 24% for general consumers, potentially reflecting veterans' familiarity with smoking from military service. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have implemented veteran-specific programs. These typically include 10-30% discounts on purchases, priority service hours, and veteran-focused product lines. Curaleaf's "Curaleaf Cares" program offers 20% discounts to veterans across its 150+ dispensaries in 23 states. Trulieve offers 10% discounts to veterans in Florida, where the company operates 190+ locations serving the state's large veteran population. The proposed rescheduling to Schedule III would eliminate Section 280E tax burdens, potentially reducing operating costs for dispensaries by 15-25% according to cannabis accounting firm Dope CFO. These savings could translate to lower prices for veteran consumers, though market dynamics suggest operators may retain savings as profit margin expansion rather than passing them to consumers. For cannabis-focused real estate investment trusts and institutional investors, veteran market stability provides attractive risk-adjusted returns. Veterans exhibit lower price sensitivity and higher brand loyalty compared to recreational consumers, according to research from Viridian Capital Advisors. This demographic stability makes dispensaries in high-veteran-population areas particularly valuable acquisition targets. Banking access remains constrained despite rescheduling momentum. The SAFER Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has not passed Congress as of May 2026. Most dispensaries serving veterans operate on cash-only basis, creating security risks and operational inefficiencies. Veterans using VA healthcare must pay cash for cannabis purchases, as credit card processors generally decline cannabis transactions. Wholesale cannabis pricing shows regional variation affecting veteran access costs. West Coast markets including California, Oregon, and Washington exhibit wholesale flower prices of $800-1,200 per pound as of early 2026, translating to retail prices of $6-10 per gram. Midwest and East Coast markets show wholesale prices of $1,800-2,800 per pound, with retail prices of $12-18 per gram. Veterans in higher-cost markets face significantly greater out-of-pocket expenses, with monthly costs ranging from $150-400 depending on consumption patterns and regional pricing. Ancillary service providers including cannabis-focused telemedicine platforms have developed veteran-specific offerings. Companies including Leafwell, Veriheal, and NuggMD offer streamlined medical marijuana evaluations, with veteran-specific marketing emphasizing PTSD and chronic pain indications. These platforms charge $99-199 for physician consultations, with some offering veteran discounts. The telemedicine model has expanded access for rural veterans who lack proximity to cannabis-friendly physicians. Insurance coverage remains absent for cannabis purchases. No private health insurance plans cover medical marijuana, and Medicare Part D explicitly excludes Schedule I substances. Even under Schedule III, coverage would require FDA approval of specific cannabis products for specific indications, a process that could take 5-10 years according to pharmaceutical development timelines. Veterans therefore bear full out-of-pocket costs, creating affordability barriers for those on fixed disability incomes.

What Experts Say About Veterans Cannabis Access

Medical researchers, policy analysts, and veterans advocates emphasize that rescheduling represents progress but falls short of comprehensive access reform needed to serve veteran populations effectively. Dr. Sue Sisley, a physician and researcher who has studied cannabis and PTSD in veterans for over a decade, said in congressional testimony that the current regulatory framework prevents rigorous clinical trials needed to establish evidence-based treatment protocols. According to Dr. Sisley, the DEA's monopoly on research-grade cannabis supply through the University of Mississippi has created a bottleneck that delays veteran-focused research by years. She emphasized that rescheduling to Schedule III would ease some research barriers but would not address the fundamental need for FDA-approved cannabis medications specifically indicated for PTSD and chronic pain. Dr. Marcel Bonn-Miller, an adjunct professor at the University of Pennsylvania Perelman School of Medicine who researches cannabis and PTSD, told the journal JAMA Psychiatry that observational data showing benefits of cannabis for veterans with PTSD must be interpreted cautiously due to selection bias and confounding variables. According to Dr. Bonn-Miller, veterans who choose to use cannabis may differ systematically from those who do not, making it difficult to isolate cannabis effects from other factors. He emphasized the need for randomized controlled trials, which remain difficult to conduct under current federal restrictions. Nick Etten, founder of Veterans Cannabis Project, said in interviews with Marijuana Moment that the VA's current policy of allowing discussion but not recommendation creates confusion for veterans and providers. According to Etten, many veterans report that VA physicians are reluctant to discuss cannabis even though policy allows it, fearing professional consequences or lacking training on cannabis pharmacology. He emphasized that comprehensive reform requires not just rescheduling but also explicit congressional authorization for VA physicians to recommend cannabis and for the VA to cover cannabis costs. The American Legion's position, articulated in its 2023 policy statement, holds that cannabis should be removed from the Controlled Substances Act entirely rather than rescheduled. According to the organization, Schedule III status would perpetuate federal-state conflicts and maintain barriers to veteran access. The Legion has called for congressional legislation explicitly authorizing VA physicians to recommend cannabis in states with medical programs and protecting veterans from federal prosecution for state-compliant cannabis use. Dr. David Shulkin, who served as VA Secretary from 2017 to 2018, said in a 2021 interview with Military Times that the VA should be allowed to conduct large-scale clinical trials on cannabis and PTSD. According to Dr. Shulkin, the evidence base for cannabis effectiveness in veterans remains insufficient for the VA to recommend it as a first-line treatment, but the only way to generate that evidence is through VA-conducted research. He noted that the VA's research infrastructure and large patient population make it ideally positioned to conduct definitive studies, but federal restrictions prevent this research from occurring. Dr. Carrie Cuttler, a clinical psychologist at Washington State University who studies cannabis effects on PTSD symptoms, told the journal Cannabis and Cannabinoid Research that her research shows acute reductions in PTSD symptoms following cannabis use, but also indicates potential for tolerance development and withdrawal symptoms with heavy long-term use. According to Dr. Cuttler, the risk-benefit profile for veterans likely varies based on individual factors, and personalized medicine approaches are needed rather than blanket recommendations for or against cannabis use. The RAND Corporation's 2021 analysis of cannabis policy and veterans concluded that state medical marijuana programs have increased veteran cannabis access but created a patchwork system with significant geographic inequities. According to the report, veterans in prohibition states or restrictive medical-only states face barriers including lack of legal access, higher prices in limited markets, and fear of federal consequences. The report recommended federal legislation to create uniform access standards and fund rigorous clinical trials.

What's Next: Decision Points and Scenarios

The next 12-24 months will determine whether veterans gain meaningful cannabis access through rescheduling implementation, congressional legislation, or continued state-by-state expansion. The Drug Enforcement Administration's rescheduling process, initiated with the May 2024 Notice of Proposed Rulemaking, includes multiple stages before final implementation. The public comment period closed in July 2024, generating over 43,000 comments, many from veterans and veterans organizations. The DEA must review comments, conduct administrative law judge hearings if objections are filed, and publish a final rule. Legal experts anticipate final rescheduling implementation in late 2026 or early 2027, though litigation could delay implementation further. Once cannabis moves to Schedule III, the Department of Veterans Affairs must issue implementation guidance for its physicians. Internal VA documents suggest the department is preparing protocols for physician training on cannabis pharmacology, prescription procedures for FDA-approved cannabis medications, and documentation requirements. However, these protocols will likely emphasize that VA physicians cannot recommend whole-plant cannabis from state dispensaries for off-label uses, limiting practical impact for most veterans. Congressional legislation represents the most direct path to comprehensive veterans cannabis access. The Veterans

Update — June 2, 2026: Advocacy groups highlight implementation gaps in VA cannabis policy

Veterans advocacy organizations renewed calls for substantive federal cannabis reform, arguing that existing VA policy changes have not translated into meaningful access for veterans seeking medical cannabis. According to a June 2 analysis published by Greenstate, while the Department of Veterans Affairs revised its guidance in recent years to allow veterans to discuss cannabis use with VA physicians without penalty, federal law still prohibits VA doctors from recommending or prescribing cannabis, leaving veterans to navigate state programs independently and without clinical support from their primary care teams.

The policy gap creates significant financial and logistical barriers for veterans in the 38 states with medical cannabis programs, according to veterans service organizations. Veterans must obtain recommendations from non-VA physicians—often at out-of-pocket costs ranging from $100 to $300—and purchase cannabis products without insurance coverage or VA reimbursement. Veterans using cannabis for conditions such as PTSD, chronic pain, or traumatic brain injury remain ineligible for VA disability benefits related to those conditions if cannabis is their primary treatment, creating a disincentive for many to pursue state-legal options.

Advocacy groups cited the disconnect between evolving state laws and federal Schedule I classification as the core obstacle. More than 4.5 million veterans currently receive care through the VA health system, according to VA statistics, yet none can access cannabis through that system even in states where medical use is legal. Legislative proposals including the Veterans Medical Marijuana Safe Harbor Act have stalled in Congress since 2019, leaving policy reform dependent on broader federal rescheduling efforts.

The operational impact extends beyond individual access: VA physicians report difficulty providing comprehensive pain management and mental health care when unable to discuss or integrate cannabis into treatment plans. Veterans advocates said the current framework forces patients to choose between VA care continuity and state-legal cannabis therapy, a choice that disproportionately affects veterans in rural areas with limited access to non-VA providers.